Vaxcyte, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report1 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+5.31%
vs ±8.6% implied · ×0.62
shaded = implied · ▲▼ = realized
No other changes.
No other changes.
No trades yet today.
No trades yet today.
Same SIC code · 6
Same SEC industry code: Amgen Inc, Gilead Sciences, Inc., Biogen Inc. and 3 more; of Vaxcyte, Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: Amgen Inc, Gilead Sciences, Inc., Biogen Inc. and 3 more; of Vaxcyte, Inc.'s 6 closest co-movers, none share that code.
Annual filing, covered
10-K parsed · Feb 24 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Feb 24 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Vaxcyte, Inc.
60.82
pre 60.50 −0.51%
| Manager | Value | % base | |
|---|---|---|---|
| FMR | $1.2B | 12.06% | +26.44% |
| Jupiter Topco | $1.0B | 10.39% | — |
| T. Rowe Price | $709.6M | 7.06% | +0.67% |
| BlackRockindex-like | $701.5M | 6.98% | +9.99% |
| RA Capital Management | $667.0M | 6.64% | 0.00% |
| Manager | Value | % base | |
|---|---|---|---|
| FMR | $1.2B | 12.06% | +26.44% |
| Jupiter Topco | $1.0B | 10.39% | — |
| T. Rowe Price | $709.6M | 7.06% | +0.67% |
| BlackRockindex-like | $701.5M | 6.98% | +9.99% |
| RA Capital Management | $667.0M | 6.64% | 0.00% |
Tall tick = annual report · Source: EDGAR
Linked news
NewsBull2
Bear1
—
Expected move
Inputs8Q avg ±5.3%·×1.09·fair
straddle ±9.9%
spot 60.81exp Nov 20ATM strike 60ATM straddle 7.08IV 68%